Clinical Trial Update: Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bulevirtide in combination with pegylated interferon alfa-2a for chronic hepatitis D has completed and posted results as of July 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis D

Drugs mentioned

• Bulevirtide (bulevirtide)
• Pegylated interferon alfa-2a (Peginterferon alfa-2a)

Snippet

Sponsor: Gilead Sciences | Conditions: Chronic Hepatitis Delta | Phase 2 | Status: COMPLETED | Results posted: 2024-07-29